組織診断市場規模、シェア、動向、2030年までの世界予測

組織診断市場は2025年に67億4,000万米ドルに達すると推定され、予測期間中に年平均成長率（CAGR）10.0%で成長し、2030年には108億6,000万米ドルに達すると予測されています。民間診断センターの設立増加は、組織診断市場に大きな影響を与えています。これらのセンターは、高度な検査サービスへのアクセスを拡大し、以前は大規模病院に限定されていた専門的な病理学および検査ソリューションを提供しています。最新の組織診断システム、消耗品、自動化されたワークフローへの投資により、民間センターは疾患検出の速度、精度、信頼性を向上させています。この傾向は、組織診断技術の採用を促進するだけでなく、より個別化されたタイムリーな患者ケアをサポートし、市場全体の成長に貢献しています。

調査対象：

本調査レポートでは、組織診断市場を、製品・サービス（消耗品、機器、ソフトウェア、サービス）、技術（免疫組織化学（IHC）、in situハイブリダイゼーション（ISH）、デジタルパソロジー、特殊染色、その他）、疾患の種類（乳がん、胃がん、リンパ腫、前立腺がん、非小細胞肺がん、その他）、エンドユーザー（病院、研究機関、製薬会社、開発業務受託機関（CRO）、その他）、地域（北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカ）別に分類しています。

本レポートは、組織診断市場の成長に影響を与える主要な要因（推進要因、制約要因、機会、課題など）に関する詳細な情報を網羅しています。主要業界プレーヤーの詳細な分析により、各社の事業概要、ソリューション、主要戦略、買収、契約に関する洞察を提供しています。本レポートでは、組織診断市場エコシステムにおける新興企業の競合分析も取り上げています。

このレポートを購入する理由：

本レポートは、組織診断市場全体および各サブセグメントの収益数値の近似値に関する情報を提供し、市場リーダー企業および新規参入企業にとって役立ちます。また、ステークホルダーが競争環境を理解し、事業のポジショニングを改善し、適切な市場開拓戦略を策定するための洞察を深めるのに役立ちます。さらに、本レポートは、ステークホルダーが市場の動向を把握し、主要な市場牽引要因、制約要因、機会、課題に関する情報を提供するのに役立ちます。

本レポートでは、以下の点について洞察を提供しています。

組織診断市場の成長に影響を与える主要な推進要因（がん罹患率の上昇、デジタル病理学への需要の高まり、医療費の増加、保険償還制度の拡充、民間診断センターの設立増加）、制約要因（組織診断システムの高コストと厳格な規制要件）、機会（新興国の高い成長機会、個別化医療への需要の高まり、がん治療薬の臨床試験件数の増加）、課題（熟練した専門家の不足、再生製品の入手可能性、TDxの標準化の不十分さ）の分析

• 製品開発／イノベーション：組織診断市場における今後の技術、研究開発活動、新製品発売に関する詳細な洞察
• 市場開発：収益性の高い市場に関する包括的な情報 ― 本レポートでは、様々な地域における組織診断市場を分析しています。
• 市場多様化：組織診断市場における新製品、未開拓地域、最近の動向、投資に関する包括的な情報
• 合評価：F. Hoffmann-La Roche Ltd（スイス）、Danaher Corporation（米国）、PHC Holdings Corporation（日本）、Agilent Technologies（米国）など、組織診断市場における主要企業の市場シェア、成長戦略、製品提供に関する詳細な評価

Report Description

The tissue diagnostics market is estimated to be USD 6.74 billion in 2025 and is projected to reach USD 10.86 billion by 2030 at a CAGR of 10.0% during the forecast period. The growing establishment of private diagnostic centers is significantly influencing the tissue diagnostics market. These centers are expanding access to advanced testing services, offering specialized pathology and laboratory solutions that were previously limited to large hospitals. By investing in modern tissue diagnostic systems, consumables, and automated workflows, private centers are enhancing the speed, accuracy, and reliability of disease detection. This trend not only increases the adoption of tissue diagnostic technologies but also supports more personalized and timely patient care, contributing to the overall growth of the market.

“By technology, the immunohistochemistry segment dominated the tissue diagnostics market  in 2024.”

Based on technology, the tissue diagnostics market is segmented into immunohistochemistry (IHC), in situ hybridization (ISH), digital pathology, special staining, and other technologies. Among these, immunohistochemistry holds a dominant position due to its broad application in detecting and visualizing specific proteins in tissue samples, which play a critical role in accurate disease diagnosis, biomarker identification, and guiding personalized treatment plans. Its ability to provide both qualitative and quantitative insights into tissue morphology and molecular expression makes it invaluable for cancer diagnostics and research. Additionally, IHC’s compatibility with automated staining systems, standardized reagents, and high-throughput workflows has further accelerated its adoption in clinical laboratories, research institutions, and pharmaceutical development. Emerging technologies like ISH and digital pathology complement IHC by offering additional molecular and imaging capabilities, but the proven reliability, versatility, and established protocols of IHC continue to drive its sustained dominance in the tissue diagnostics market.

“By disease type, the breast cancer segment is projected to achieve the highest growth during the forecast period.”

The tissue diagnostics market is segmented based on disease types into breast cancer, gastric cancer, lymphoma, prostate cancer, non-small cell lung cancer (NSCLC), and other disease types. Among these, the breast cancer segment is expected to register the highest growth during the forecast period. This rapid expansion is driven by the increasing global incidence of breast cancer, heightened awareness of early detection, and growing adoption of advanced diagnostic tools for accurate biomarker identification. Innovations in tissue diagnostics, including IHC panels and multiplex assays, are further enabling precise subtyping and risk stratification, supporting personalized treatment decisions. These factors collectively position the breast cancer segment as the fastest-growing area within the tissue diagnostics market.

“Asia Pacific is projected to be the fastest-growing regional market during the forecast period.” ”

The market for tissue diagnostics is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is expected to register the highest growth during the forecast period. Rapidly expanding healthcare infrastructure, increasing government initiatives for early disease detection, and rising awareness about cancer screening are key factors driving market expansion in the region. Additionally, growing investments in research and development, the increasing prevalence of cancer, and the adoption of advanced diagnostic technologies in emerging economies such as China, India, and Japan are further accelerating market growth. These trends make Asia Pacific a high-potential region for tissue diagnostics in the coming years.

Break-up of the profiles of primary participants in the tissue diagnostics market:

• By Company Type: Tier 1 – 40%, Tier 2 – 30%, and Tier 3 – 30%
• By Designation: C-level – 27%, D-level – 18%, and Others – 55%
• By Region: North America – 51%, Europe – 21%, Asia Pacific – 18%, Latin America – 6%, and Middle East & Africa- 4%

The key players in the tissue diagnostics market are F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), PHC Holdings Corporation (Epredia) (Japan), Abbott (US), Agilent Technologies (US), Merck KGaA (Germany), Sakura Finetek Japan Co., Ltd. (Japan), Becton, Dickinson and Company (US), BioGenex (US), Bio SB (US), Cell Signaling Technology, Inc. (US), Histo-Line Laboratories (Italy), SLEE medical GmbH (Germany), Amos Scientific Pty Ltd. (Australia), Jinhua YIDI Medical Appliance Co., Ltd. (China), MEDITE Medical GmbH (Germany), StatLab Medical Products (UK), KONFOONG BIOINFORMATION TECH Co., Ltd. (China), Diagnostic BioSystems Inc. (US), 3DHISTECH (Hungary), RWD Life Science Co., Ltd. (US), Dakewe (China), Battery Ventures (Enzo Biochem Inc.) (US), Biocare Medical, LLC. (US), MILESTONE MEDICAL (Italy), Bio-Optica Milano Spa (Italy), and BioGnost d.o.o. (Croatia).

Research Coverage:

This research report categorizes the tissue diagnostics market by product & service (consumables, instruments, software, and services), technology (immunohistochemistry (IHC), in situ hybridization (ISH), digital pathology, special staining, and other technologies), disease type (breast cancer, gastric cancer, lymphoma, prostate cancer, non-small cell lung cancer, other disease types), end user [hospitals, research laboratories, pharmaceutical companies, contract research organizations (CROs), and other end users], and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa).

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges, influencing the growth of the tissue diagnostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements.  Competitive analysis of upcoming startups in the tissue diagnostics market ecosystem is covered in this report.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall tissue diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (Rising prevalence of cancer, Growing demand for digital pathology, Increasing healthcare expenditure, Growing availability of reimbursements, and Rising establishment of private diagnostic centers), restraints (High cost of tissue diagnostic systems and Stringent regulatory requirements), opportunities (High growth opportunities of emerging economies, Growing demand for personalized medicines, Increasing number of clinical trials for cancer therapeutics), and challenges (Shortage of skilled professionals, Availability of refurbished products, and Inadequate standardization for TDx) influencing the growth of the tissue diagnostics market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the tissue diagnostics market
• Market Development: Comprehensive information about lucrative markets – the report analyses the tissue diagnostics market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the tissue diagnostics market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (US), PHC Holdings Corporation (Japan), Agilent Technologies (US), among others, in the tissue diagnostics market

Table of Contents

1 INTRODUCTION 39
1.1 STUDY OBJECTIVES 39
1.2 MARKET DEFINITION 39
1.3 STUDY SCOPE 40
1.3.1 MARKETS COVERED AND REGIONAL SCOPE 40
1.3.2 INCLUSIONS AND EXCLUSIONS 41
1.3.3 YEARS CONSIDERED 42
1.4 CURRENCY CONSIDERED 42
1.5 STAKEHOLDERS 42
1.6 SUMMARY OF CHANGES 43
2 EXECUTIVE SUMMARY 44
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 44
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 45
2.3 DISRUPTIVE TRENDS SHAPING MARKET 46
2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS 47
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 48
3 PREMIUM INSIGHTS 49
3.1 TISSUE DIAGNOSTICS MARKET OVERVIEW 49
3.2 TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 50
3.3 TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030 50
3.4 TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2025 VS. 2030 51
3.5 TISSUE DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 51
3.6 TISSUE DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 52
4 MARKET OVERVIEW 53
4.1 INTRODUCTION 53
4.2 MARKET DYNAMICS 53
4.2.1 DRIVERS 54
4.2.1.1 Rising incidence of cancer 54
4.2.1.2 Growing demand for digital pathology 56
4.2.1.3 Increasing healthcare expenditure 57
4.2.1.4 Growing availability of reimbursements 57
4.2.1.5 Rising establishment of private diagnostic centers 58
4.2.2 RESTRAINTS 59
4.2.2.1 High cost of tissue diagnostic systems 59
4.2.2.2 Stringent regulatory requirements 59

4.2.3 OPPORTUNITIES 59
4.2.3.1 High growth potential in emerging economies 59
4.2.3.2 Growing preference for personalized medicines 60
4.2.3.3 Increasing number of clinical trials for cancer therapeutics 61
4.2.4 CHALLENGES 62
4.2.4.1 Shortage of skilled professionals 62
4.2.4.2 Availability of refurbished products 62
4.2.4.3 Inadequate standardization 62
4.3 UNMET NEEDS AND WHITE SPACES 63
4.3.1 UNMET NEEDS 63
4.3.2 WHITE SPACE OPPORTUNITIES 64
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 64
4.4.1 CROSS-SECTOR OPPORTUNITIES 65
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 65
5 INDUSTRY TRENDS 66
5.1 PORTER’S FIVE FORCES ANALYSIS 66
5.1.1 THREAT OF NEW ENTRANTS 67
5.1.2 BARGAINING POWER OF BUYERS 67
5.1.3 BARGAINING POWER OF SUPPLIERS 67
5.1.4 THREAT OF SUBSTITUTES 67
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 67
5.2 MACROECONOMIC OUTLOOK 68
5.2.1 INTRODUCTION 68
5.2.2 GDP TRENDS AND FORECAST 68
5.3 SUPPLY CHAIN ANALYSIS 71
5.4 VALUE CHAIN ANALYSIS 72
5.5 ECOSYSTEM ANALYSIS 73
5.6 PRICING ANALYSIS 75
5.6.1 AVERAGE SELLING PRICE TREND, BY PRODUCT, 2023–2025 75
5.6.2 AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2023–2025 76
5.6.3 AVERAGE SELLING PRICE TREND, BY REGION, 2023–2025 77
5.7 TRADE ANALYSIS 78
5.7.1 IMPORT DATA (HS CODE 3822) 78
5.7.2 EXPORT DATA (HS CODE 3822) 79
5.8 KEY CONFERENCES AND EVENTS, 2025–2026 79
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 80
5.10 INVESTMENT AND FUNDING SCENARIO 81
5.11 CASE STUDY ANALYSIS 81
5.11.1 CASE STUDY 1: OPTIMIZING AUTOMATED TISSUE PROCESSING EFFICIENCY TO REDUCE COST 81
5.11.2 CASE STUDY 2: OPERATIONAL EFFICIENCY IMPROVEMENTS THROUGH MILESTONE MEDICAL TISSUE PROCESSOR IMPLEMENTATION 82
5.11.3 CASE STUDY 3: WORKFLOW OPTIMIZATION THROUGH EXCELSIOR AS TISSUE PROCESSOR 82
5.12 IMPACT OF 2025 US TARIFFS ON TISSUE DIAGNOSTICS MARKET 83
5.12.1 INTRODUCTION 83
5.12.2 KEY TARIFF RATES 83
5.12.3 PRICE IMPACT ANALYSIS 84
5.12.4 KEY IMPACT ON COUNTRY/REGION 84
5.12.4.1 North America 84
5.12.4.2 Europe 84
5.12.4.3 Asia Pacific 85
5.12.5 IMPACT ON END-USE INDUSTRIES 85
5.12.5.1 Hospitals 85
5.12.5.2 Research laboratories 85
5.12.5.3 Pharmaceutical companies 85
5.12.5.4 Contract research organizations (CROs) 85
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 86
6.1 KEY EMERGING TECHNOLOGIES 86
6.1.1 IMMUNOHISTOCHEMISTRY (IHC) 86
6.1.2 IN SITU HYBRIDIZATION (ISH) 86
6.1.3 DIGITAL PATHOLOGY 86
6.2 COMPLEMENTARY TECHNOLOGIES 87
6.2.1 SPECIAL STAINING 87
6.2.2 MASS SPECTROMETRY IMAGING (MSI) 87
6.3 TECHNOLOGY/PRODUCT ROADMAP 87
6.3.1 SHORT-TERM (2025–2027) | OPTIMIZATION & STANDARDIZATION OF CORE REAGENTS 87
6.3.1.1 Core technology development 87
6.3.1.2 Product innovations 88
6.3.1.3 Market adoption 88
6.3.2 MID-TERM (2027–2030) | EXPANDED CAPABILITIES & SUSTAINABILITY 88
6.3.2.1 Advanced technology development 88
6.3.2.2 Product innovations 88
6.3.2.3 Market adoption 88
6.3.3 LONG-TERM (2030–2035+) | HIGH-PERFORMANCE & ECO-EFFICIENT TISSUE DIAGNOSTICS PRODUCTS 89
6.3.3.1 High-performance & integrated workflows 89
6.3.3.2 Product innovations 89
6.3.3.3 Market adoption 89

6.4 PATENT ANALYSIS 90
6.5 FUTURE APPLICATIONS 92
6.6 IMPACT OF AI/GENERATIVE AI ON TISSUE DIAGNOSTICS MARKET 92
6.6.1 TOP USE CASES AND MARKET POTENTIAL 93
6.6.2 BEST PRACTICES IN TISSUE DIAGNOSTICS MARKET 93
6.6.3 CASE STUDIES OF AI IMPLEMENTATION IN TISSUE DIAGNOSTICS MARKET 94
6.6.4 FUTURE OF AI IN TISSUE DIAGNOSTICS MARKET 95
6.6.5 INTERCONNECTED ADJACENT ECOSYSTEMS AND IMPACT ON MARKET PLAYERS 95
6.6.6 CLIENTS’ READINESS TO ADOPT GENERATIVE AND AI-ENABLED TECHNOLOGIES IN TISSUE DIAGNOSTICS MARKET 96
7 SUSTAINABILITY AND REGULATORY LANDSCAPE 97
7.1 REGIONAL REGULATIONS AND COMPLIANCE 97
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97
7.1.2 INDUSTRY STANDARDS 99
7.2 SUSTAINABILITY INITIATIVES 99
7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN TISSUE DIAGNOSTICS 99
7.2.1.1 Eco-friendly initiatives 100
7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES 101
7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 102
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 103
8.1 DECISION-MAKING PROCESS 103
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 103
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 103
8.2.2 BUYING CRITERIA 104
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 105
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 106
8.5 MARKET PROFITABILITY 107
8.5.1 REVENUE POTENTIAL 107
8.5.2 COST DYNAMICS 107
8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 107
9 TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 108
9.1 INTRODUCTION 109
9.2 CONSUMABLES 109
9.2.1 ANTIBODIES 112
9.2.1.1 Primary antibodies 114
9.2.1.1.1 Expanding clinical applications and biomarker discovery to drive market 114

9.2.1.2 Secondary antibodies 117
9.2.1.2.1 Rising adoption of digital pathology to boost market 117
9.2.2 KITS 119
9.2.2.1 Human immunohistochemistry kits 122
9.2.2.1.1 Expanding cancer screening and biomarker testing to fuel market 122
9.2.2.2 Animal immunohistochemistry kits 124
9.2.2.2.1 Growing preclinical and comparative studies to propel market 124
9.2.3 REAGENTS 127
9.2.3.1 Blocking sera and reagents 129
9.2.3.1.1 Rising emphasis on diagnostic accuracy to support growth 129
9.2.3.2 Chromogenic substrates 132
9.2.3.2.1 Increasing demand for high-sensitivity chromogenic substrates to fuel market 132
9.2.3.3 Fixation reagents 134
9.2.3.3.1 Growing emphasis on tissue integrity and biomarker preservation to drive market 134
9.2.3.4 Organic solvents 137
9.2.3.4.1 Increasing focus on solvent safety and efficiency to spur growth 137
9.2.3.5 Proteolytic enzymes 139
9.2.3.5.1 Need for handling complex tissue samples and multiplexed biomarker panels to facilitate growth 139
9.2.3.6 Diluents 141
9.2.3.6.1 Rising focus on maintaining reagent stability to support growth 141
9.2.3.7 Other reagents 143
9.2.4 PROBES 146
9.2.4.1 Utilization of probes in fluorescence microscopy applications to boost market 146
9.3 INSTRUMENTS 148
9.3.1 SLIDE-STAINING SYSTEMS 151
9.3.1.1 H&E stainers 153
9.3.1.1.1 Increasing patient volume to sustain growth 153
9.3.1.2 Special stainers 155
9.3.1.2.1 Growing demand for targeted visualization to fuel market 155
9.3.1.3 IHC stainers 158
9.3.1.3.1 Growing demand for high-throughput tissue analysis and multiplex biomarker panels to drive market 158
9.3.2 MICROTOMES 160
9.3.2.1 Increasing demand for accurate tissue sectioning to support growth 160
9.3.3 DIGITAL PATHOLOGY SCANNERS 163
9.3.3.1 Growing adoption of digital imaging to propel market 163

9.3.4 TISSUE PROCESSING SYSTEMS 166
9.3.4.1 Rising need for automation in tissue preparation to propel market 166
9.3.5 OTHER INSTRUMENTS 168
9.4 SOFTWARE 171
9.4.1 INCREASING WORKFLOW DIGITIZATION AND DATA MANAGEMENT NEEDS TO DRIVE MARKET 171
9.5 SERVICES 173
9.5.1 RISING ADOPTION OF COMPANION DIAGNOSTICS TO EXPEDITE GROWTH 173
10 TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY 175
10.1 INTRODUCTION 176
10.2 IMMUNOHISTOCHEMISTRY 176
10.2.1 RISING UPTAKE OF IMMUNOHISTOCHEMISTRY KITS FOR DIAGNOSTIC APPLICATIONS TO FUEL MARKET 176
10.3 IN SITU HYBRIDIZATION 179
10.3.1 ABILITY TO DETECT SPECIFIC RNA AND DNA SEQUENCES TO BOOST MARKET 179
10.4 DIGITAL PATHOLOGY 182
10.4.1 RISING NEED FOR ANALYSIS AND SEAMLESS MANAGEMENT TO SUPPORT GROWTH 182
10.5 SPECIAL STAINING 184
10.5.1 UTILIZATION OF SPECIAL STAINING IN CANCER DIAGNOSTICS TO PROPEL MARKET 184
11 TISSUE DIAGNOSTICS MARKET, BY DISEASE 187
11.1 INTRODUCTION 188
11.2 BREAST CANCER 189
11.2.1 RISING UPTAKE OF HER2 TESTS FOR CANCER DIAGNOSIS TO FUEL MARKET 189
11.3 GASTRIC CANCER 192
11.3.1 RISING INCIDENCE OF GASTROINTESTINAL CANCER TO BOOST MARKET 192
11.4 LYMPHOMA 194
11.4.1 RISING INCIDENCE OF NON-HODGKIN’S LYMPHOMA IN ADULTS TO SUPPORT GROWTH 194
11.5 PROSTATE CANCER 197
11.5.1 GROWING RATE OF PROSTATE CANCER TO PROPEL MARKET 197
11.6 NON-SMALL CELL LUNG CANCER 199
11.6.1 GROWING FOCUS ON DEVELOPING COMPANION DIAGNOSTIC TESTS TO DRIVE MARKET 199
11.7 OTHER DISEASE TYPES 202
12 US: NUMBER OF TISSUE DIAGNOSTICS TESTS, BY SAMPLE TYPE 205

13 TISSUE DIAGNOSTICS MARKET, BY END USER 206
13.1 INTRODUCTION 207
13.2 HOSPITALS 207
13.2.1 INCREASING NUMBER OF SPECIALTY DIAGNOSTIC TESTS TO DRIVE MARKET 207
13.3 RESEARCH LABORATORIES 210
13.3.1 RISING DEMAND OF SPECIALTY TESTS TO DRIVE MARKET 210
13.4 PHARMACEUTICAL COMPANIES 212
13.4.1 INCREASING R&D ACTIVITIES FOR DISEASE DIAGNOSTICS TO DRIVE MARKET 212
13.5 CONTRACT RESEARCH ORGANIZATIONS 214
13.5.1 GROWING DEMAND FOR OUTSOURCING ANALYTICAL TESTING & CLINICAL TRIAL SERVICES TO BOOST MARKET 214
13.6 OTHER END USERS 216
14 TISSUE DIAGNOSTICS MARKET, BY REGION 219
14.1 INTRODUCTION 220
14.2 NORTH AMERICA 220
14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 221
14.2.2 US 226
14.2.2.1 High healthcare expenditure to drive market 226
14.2.3 CANADA 231
14.2.3.1 Rising prevalence of cancer to fuel market 231
14.3 EUROPE 236
14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 237
14.3.2 GERMANY 241
14.3.2.1 Favorable government initiatives to boost market 241
14.3.3 FRANCE 246
14.3.3.1 Increasing demand for cancer diagnostics to propel market 246
14.3.4 UK 251
14.3.4.1 Rising investments in cancer research to drive market 251
14.3.5 ITALY 255
14.3.5.1 High incidence of cancer and geriatric population to support growth 255
14.3.6 SPAIN 260
14.3.6.1 Increasing cancer cases to boost market 260
14.3.7 REST OF EUROPE 264
14.4 ASIA PACIFIC 268
14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 269
14.4.2 CHINA 274
14.4.2.1 Increasing focus on healthcare infrastructure to boost market 274
14.4.3 JAPAN 278
14.4.3.1 Rise in development of advanced diagnostic products to fuel market 278

14.4.4 INDIA 283
14.4.4.1 Presence of large patient pool and rapdily growing healthcare sector to drive market 283
14.4.5 REST OF ASIA PACIFIC 288
14.5 LATIN AMERICA 292
14.5.1 MACROEOCNOMIC OUTLOOK FOR LATIN AMERICA 293
14.5.2 BRAZIL 297
14.5.2.1 Increasing burden of cancer cases to aid growth 297
14.5.3 MEXICO 301
14.5.3.1 Growing cancer burden to boost market 301
14.5.4 REST OF LATIN AMERICA 305
14.6 MIDDLE EAST & AFRICA 309
14.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 310
15 COMPETITIVE LANDSCAPE 315
15.1 OVERVIEW 315
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022–2025 315
15.3 REVENUE ANALYSIS, 2022–2024 317
15.4 MARKET SHARE ANALYSIS, 2024 317
15.5 BRAND COMPARISON 320
15.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 321
15.6.1 STARS 321
15.6.2 EMERGING LEADERS 321
15.6.3 PERVASIVE PLAYERS 321
15.6.4 PARTICIPANTS 321
15.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 323
15.6.5.1 Company footprint 323
15.6.5.2 Region footprint 323
15.6.5.3 Product & service footprint 324
15.6.5.4 Technology footprint 325
15.6.5.5 End-user footprint 325
15.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 326
15.7.1 PROGRESSIVE COMPANIES 326
15.7.2 RESPONSIVE COMPANIES 326
15.7.3 DYNAMIC COMPANIES 326
15.7.4 STARTING BLOCKS 326
15.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 328
15.7.5.1 Detailed list of key startups/SMEs 328
15.7.5.2 Competitive benchmarking of key startups/SMEs 329
15.8 COMPANY VALUATION AND FINANCIAL METRICS 329

15.9 COMPETITIVE SCENARIO 330
15.9.1 PRODUCT LAUNCHES AND APPROVALS 330
15.9.2 DEALS 331
15.9.3 EXPANSIONS 332
16 COMPANY PROFILES 334
16.1 KEY PLAYERS 334
16.1.1 F. HOFFMANN-LA ROCHE LTD. 334
16.1.1.1 Business overview 334
16.1.1.2 Products offered 335
16.1.1.3 Recent developments 337
16.1.1.3.1 Product launches and approvals 337
16.1.1.4 MnM view 338
16.1.1.4.1 Key strengths/Right to win 338
16.1.1.4.2 Strategic choices 339
16.1.1.4.3 Weaknesses/Competitive threats 339
16.1.2 DANAHER CORPORATION 340
16.1.2.1 Business overview 340
16.1.2.2 Products offered 341
16.1.2.3 Recent developments 343
16.1.2.3.1 Product launches and approvals 343
16.1.2.3.2 Deals 343
16.1.2.4 MnM view 344
16.1.2.4.1 Key strengths/Right to win 344
16.1.2.4.2 Strategic choices 345
16.1.2.4.3 Weaknesses/Competitive threats 345
16.1.3 AGILENT TECHNOLOGIES, INC. 346
16.1.3.1 Business overview 346
16.1.3.2 Products offered 347
16.1.3.3 Recent developments 348
16.1.3.3.1 Deals 348
16.1.3.4 MnM view 349
16.1.3.4.1 Key strengths/Right to win 349
16.1.3.4.2 Strategic choices 349
16.1.3.4.3 Weaknesses/Competitive threats 349
16.1.4 PHC HOLDINGS CORPORATION (EPREDIA) 350
16.1.4.1 Business overview 350
16.1.4.2 Products offered 351
16.1.4.3 Recent developments 352
16.1.4.3.1 Product approvals 352
16.1.4.3.2 Deals 352

16.1.4.4 MnM view 353
16.1.4.4.1 Key strengths/Right to win 353
16.1.4.4.2 Strategic choices 353
16.1.4.4.3 Weaknesses/Competitive threats 353
16.1.5 MERCK KGAA 354
16.1.5.1 Business overview 354
16.1.5.2 Products offered 355
16.1.5.3 Recent developments 356
16.1.5.3.1 Expansions 356
16.1.5.4 MnM view 356
16.1.5.4.1 Key strengths/Right to win 356
16.1.5.4.2 Strategic choices 356
16.1.5.4.3 Weaknesses/Competitive threats 357
16.1.6 ABBOTT 358
16.1.6.1 Business overview 358
16.1.6.2 Products offered 360
16.1.7 BECTON, DICKINSON AND COMPANY 361
16.1.7.1 Business overview 361
16.1.7.2 Products offered 362
16.1.7.3 Recent developments 363
16.1.7.3.1 Expansions 363
16.1.8 SYSMEX CORPORATION 364
16.1.8.1 Business overview 364
16.1.8.2 Products offered 365
16.1.8.3 Recent developments 366
16.1.8.3.1 Product launches and approvals 366
16.1.8.3.2 Deals 366
16.1.9 SAKURA FINETEK JAPAN CO., LTD. 367
16.1.9.1 Business overview 367
16.1.9.2 Products offered 367
16.1.9.3 Recent developments 368
16.1.9.3.1 Product launches and approvals 368
16.1.9.3.2 Deals 370
16.1.9.3.3 Expansions 370
16.1.10 BIOGENEX 371
16.1.10.1 Business overview 371
16.1.10.2 Products offered 371
16.1.10.3 Recent developments 372
16.1.10.3.1 Product launches and approvals 372
16.1.11 BIO SB 373
16.1.11.1 Business overview 373
16.1.11.2 Products offered 374
16.1.12 CELL SIGNALING TECHNOLOGY, INC. 375
16.1.12.1 Business overview 375
16.1.12.2 Products offered 375
16.1.12.3 Recent developments 375
16.1.12.3.1 Deals 375
16.1.13 HISTO-LINE LABORATORIES 377
16.1.13.1 Business overview 377
16.1.13.2 Products offered 377
16.1.14 SLEE MEDICAL GMBH 379
16.1.14.1 Business overview 379
16.1.14.2 Products offered 379
16.2 OTHER PLAYERS 381
16.2.1 AMOS SCIENTIFIC PTY LTD. 381
16.2.2 JINHUA YIDI MEDICAL APPLIANCE CO., LTD. 382
16.2.3 MEDITE MEDICAL GMBH 383
16.2.4 SLMP, LLC 384
16.2.5 KONFOONG BIOINFORMATION TECH CO., LTD (KFBIO) 385
16.2.6 DIAGNOSTIC BIOSYSTEMS INC. 386
16.2.7 3DHISTECH LTD. 387
16.2.8 RWD LIFE SCIENCE CO., LTD. 388
16.2.9 DAKEWE 389
16.2.10 BATTERY VENTURES (ENZO BIOCHEM INC.) 390
16.2.11 BIOCARE MEDICAL, LLC. 391
16.2.12 MILESTONE SRL 392
16.2.13 BIO-OPTICA MILANO SPA 393
16.2.14 BIOGNOST D.O.O. 394
16.2.15 OPTRASCAN 395
16.2.16 CLARAPATH 396
17 RESEARCH METHODOLOGY 397
17.1 RESEARCH DATA 397
17.1.1 SECONDARY DATA 397
17.1.1.1 Key data from secondary sources 398
17.1.2 PRIMARY DATA 398
17.1.2.1 Key data from primary sources 399
17.1.2.2 Key primary participants 400
17.1.2.3 Breakdown of primary interviews 401
17.1.2.4 Key industry insights 402
17.2 MARKET SIZE ESTIMATION 402
17.2.1 BOTTOM-UP APPROACH 402
17.2.1.1 Revenue estimation of key players 403
17.2.1.2 Study of annual reports and investor presentations 403
17.2.1.3 Primary interviews 403
17.2.1.4 Growth forecast 403
17.2.2 TOP-DOWN APPROACH 404
17.2.3 BASE NUMBER CALCULATION 405
17.3 MARKET FORECAST APPROACH 405
17.4 DATA TRIANGULATION 407
17.5 FACTOR ANALYSIS 408
17.6 RESEARCH ASSUMPTIONS 409
17.6.1 PARAMETRIC ASSUMPTIONS 409
17.6.2 GROWTH RATE ASSUMPTIONS 409
17.7 RESEARCH LIMITATIONS AND RISK ASSESSMENT 410
17.7.1 RESEARCH LIMITATIONS 410
17.7.2 RISK ASSESSMENT 411
18 APPENDIX 412
18.1 DISCUSSION GUIDE 412
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 416
18.3 CUSTOMIZATION OPTIONS 418
18.4 RELATED REPORTS 418
18.5 AUTHOR DETAILS 419

LIST OF TABLES

TABLE 1 PROJECTED INCREASE IN CANCER PATIENTS, 2022 VS. 2035 VS. 2050,
BY REGION 55
TABLE 2 PROJECTED INCREASE IN GLOBAL NUMBER OF CANCER PATIENTS, BY TYPE,
2022 VS. 2045 55
TABLE 3 INTERCONNECTED MARKETS 64
TABLE 4 KEY MOVES AND STRATEGIC FOCUS 65
TABLE 5 IMPACT OF PORTER’S FORCES ON TISSUE DIAGNOSTICS MARKET 67
TABLE 6 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030 68
TABLE 7 NORTH AMERICA: MACROECONOMIC INDICATORS 69
TABLE 8 EUROPE: MACROECONOMIC INDICATORS 70
TABLE 9 ASIA PACIFIC: MACROECONOMIC INDICATORS 70
TABLE 10 LATIN AMERICA: MACROECONOMIC INDICATORS 70
TABLE 11 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 70
TABLE 12 TISSUE DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM 74
TABLE 13 AVERAGE SELLING PRICE TREND, BY PRODUCT, 2023–2025 (USD) 76
TABLE 14 AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2023–2025 (USD) 76
TABLE 15 AVERAGE SELLING PRICE TREND, BY REGION, 2023–2025 (USD) 77
TABLE 16 IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY,
2020–2024 (USD MILLION) 78
TABLE 17 EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY,
2020–2024 (USD MILLION) 79
TABLE 18 TISSUE DIAGNOSTICS MARKET: KEY CONFERENCES AND EVENTS, 2025–2026 79
TABLE 19 US-ADJUSTED RECIPROCAL TARIFF RATES 83
TABLE 20 TISSUE DIAGNOSTICS MARKET: LIST OF MAJOR PATENTS, 2023–2025 91
TABLE 21 CLIENT’S READINESS TO ADOPT AI AND GENERATIVE TECHNOLOGIES IN TISSUE DIAGNOSTICS MARKET 96
TABLE 22 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97
TABLE 23 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97
TABLE 24 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98
TABLE 25 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98
TABLE 26 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 99
TABLE 27 TISSUE DIAGNOSTICS MARKET: GLOBAL STANDARDS 99
TABLE 28 TISSUE DIAGNOSTICS MARKET: CERTIFICATIONS, LABELING, AND ECO-STANDARDS 102
TABLE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%) 104
TABLE 30 KEY BUYING CRITERIA, BY END USER 104
TABLE 31 ADOPTION BARRIERS & INTERNAL CHALLENGES 105
TABLE 32 TISSUE DIAGNOSTICS MARKET: UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 106
TABLE 33 TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 109
TABLE 34 TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE,
2023–2030 (USD MILLION) 110
TABLE 35 TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY REGION,
2023–2030 (USD MILLION) 110
TABLE 36 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES,
BY COUNTRY, 2023–2030 (USD MILLION) 110
TABLE 37 EUROPE: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION) 111
TABLE 38 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION) 111
TABLE 39 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES,
BY COUNTRY, 2023–2030 (USD MILLION) 111
TABLE 40 TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE,
2023–2030 (USD MILLION) 112
TABLE 41 TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY REGION,
2023–2030 (USD MILLION) 113
TABLE 42 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 113
TABLE 43 EUROPE: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY COUNTRY,
2023–2030 (USD MILLION) 113
TABLE 44 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 114
TABLE 45 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 114
TABLE 46 PRIMARY ANTIBODIES AVAILABLE IN MARKET 115
TABLE 47 TISSUE DIAGNOSTICS MARKET FOR PRIMARY ANTIBODIES, BY REGION,
2023–2030 (USD MILLION) 115
TABLE 48 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR PRIMARY ANTIBODIES,
BY COUNTRY, 2023–2030 (USD MILLION) 116
TABLE 49 EUROPE: TISSUE DIAGNOSTICS MARKET FOR PRIMARY ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 116
TABLE 50 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR PRIMARY ANTIBODIES,
BY COUNTRY, 2023–2030 (USD MILLION) 116
TABLE 51 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR PRIMARY ANTIBODIES,
BY COUNTRY, 2023–2030 (USD MILLION) 117
TABLE 52 SECONDARY ANTIBODIES AVAILABLE IN MARKET 117
TABLE 53 TISSUE DIAGNOSTICS MARKET FOR SECONDARY ANTIBODIES, BY REGION,
2023–2030 (USD MILLION) 118
TABLE 54 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR SECONDARY ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 118
TABLE 55 EUROPE: TISSUE DIAGNOSTICS MARKET FOR SECONDARY ANTIBODIES,
BY COUNTRY, 2023–2030 (USD MILLION) 118
TABLE 56 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR SECONDARY ANTIBODIES,
BY COUNTRY, 2023–2030 (USD MILLION) 119
TABLE 57 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR SECONDARY ANTIBODIES,
BY COUNTRY, 2023–2030 (USD MILLION) 119
TABLE 58 TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023–2030 (USD MILLION) 120
TABLE 59 TISSUE DIAGNOSTICS MARKET FOR KITS, BY REGION, 2023–2030 (USD MILLION) 120
TABLE 60 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR KITS, BY COUNTRY,
2023–2030 (USD MILLION) 120
TABLE 61 EUROPE: TISSUE DIAGNOSTICS MARKET FOR KITS, BY COUNTRY,
2023–2030 (USD MILLION) 121
TABLE 62 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR KITS, BY COUNTRY,
2023–2030 (USD MILLION) 121
TABLE 63 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR KITS, BY COUNTRY,
2023–2030 (USD MILLION) 121
TABLE 64 HUMAN IMMUNOHISTOCHEMISTRY KITS AVAILABLE IN MARKET 122
TABLE 65 TISSUE DIAGNOSTICS MARKET FOR HUMAN IMMUNOHISTOCHEMISTRY KITS,
BY REGION, 2023–2030 (USD MILLION) 123
TABLE 66 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR HUMAN IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2023–2030 (USD MILLION) 123
TABLE 67 EUROPE: TISSUE DIAGNOSTICS MARKET FOR HUMAN IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2023–2030 (USD MILLION) 123
TABLE 68 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR HUMAN IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2023–2030 (USD MILLION) 124
TABLE 69 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR HUMAN IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2023–2030 (USD MILLION) 124
TABLE 70 ANIMAL IMMUNOHISTOCHEMISTRY KITS AVAILABLE IN MARKET 125
TABLE 71 TISSUE DIAGNOSTICS MARKET FOR ANIMAL IMMUNOHISTOCHEMISTRY KITS,
BY REGION, 2023–2030 (USD MILLION) 125
TABLE 72 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR ANIMAL IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2023–2030 (USD MILLION) 125
TABLE 73 EUROPE: TISSUE DIAGNOSTICS MARKET FOR ANIMAL IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2023–2030 (USD MILLION) 126
TABLE 74 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR ANIMAL IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2023–2030 (USD MILLION) 126
TABLE 75 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR ANIMAL IMMUNOHISTOCHEMISTRY KITS, BY COUNTRY, 2023–2030 (USD MILLION) 126
TABLE 76 TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE,
2023–2030 (USD MILLION) 127
TABLE 77 TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY REGION,
2023–2030 (USD MILLION) 128
TABLE 78 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION) 128
TABLE 79 EUROPE: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY COUNTRY,
2023–2030 (USD MILLION) 128
TABLE 80 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION) 129
TABLE 81 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION) 129
TABLE 82 BLOCKING SERA & REAGENTS AVAILABLE IN MARKET 130
TABLE 83 TISSUE DIAGNOSTICS MARKET FOR BLOCKING SERA & REAGENTS, BY REGION, 2023–2030 (USD MILLION) 130
TABLE 84 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR BLOCKING SERA & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION) 130
TABLE 85 EUROPE: TISSUE DIAGNOSTICS MARKET FOR BLOCKING SERA & REAGENTS,
BY COUNTRY, 2023–2030 (USD MILLION) 131
TABLE 86 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR BLOCKING SERA & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION) 131
TABLE 87 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR BLOCKING SERA & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION) 131
TABLE 88 CHROMOGENIC SUBSTRATES AVAILABLE IN MARKET 132
TABLE 89 TISSUE DIAGNOSTICS MARKET FOR CHROMOGENIC SUBSTRATES, BY REGION, 2023–2030 (USD MILLION) 133
TABLE 90 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR CHROMOGENIC SUBSTRATES, BY COUNTRY, 2023–2030 (USD MILLION) 133
TABLE 91 EUROPE: TISSUE DIAGNOSTICS MARKET FOR CHROMOGENIC SUBSTRATES,
BY COUNTRY, 2023–2030 (USD MILLION) 133
TABLE 92 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR CHROMOGENIC SUBSTRATES, BY COUNTRY, 2023–2030 (USD MILLION) 134
TABLE 93 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR CHROMOGENIC SUBSTRATES, BY COUNTRY, 2023–2030 (USD MILLION) 134
TABLE 94 FIXATION REAGENTS AVAILABLE IN MARKET 135
TABLE 95 TISSUE DIAGNOSTICS MARKET FOR FIXATION REAGENTS, BY REGION,
2023–2030 (USD MILLION) 135
TABLE 96 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR FIXATION REAGENTS,
BY COUNTRY, 2023–2030 (USD MILLION) 135
TABLE 97 EUROPE: TISSUE DIAGNOSTICS MARKET FOR FIXATION REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION) 136
TABLE 98 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR FIXATION REAGENTS,
BY COUNTRY, 2023–2030 (USD MILLION) 136
TABLE 99 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR FIXATION REAGENTS,
BY COUNTRY, 2023–2030 (USD MILLION) 136
TABLE 100 TISSUE DIAGNOSTICS MARKET FOR ORGANIC SOLVENTS, BY REGION,
2023–2030 (USD MILLION) 137
TABLE 101 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR ORGANIC SOLVENTS,
BY COUNTRY, 2023–2030 (USD MILLION) 137
TABLE 102 EUROPE: TISSUE DIAGNOSTICS MARKET FOR ORGANIC SOLVENTS, BY COUNTRY, 2023–2030 (USD MILLION) 138
TABLE 103 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR ORGANIC SOLVENTS,
BY COUNTRY, 2023–2030 (USD MILLION) 138
TABLE 104 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR ORGANIC SOLVENTS,
BY COUNTRY, 2023–2030 (USD MILLION) 138
TABLE 105 PROTEOLYTIC ENZYMES AVAILABLE IN MARKET 139
TABLE 106 TISSUE DIAGNOSTICS MARKET FOR PROTEOLYTIC ENZYMES, BY REGION,
2023–2030 (USD MILLION) 139
TABLE 107 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR PROTEOLYTIC ENZYMES,
BY COUNTRY, 2023–2030 (USD MILLION) 140
TABLE 108 EUROPE: TISSUE DIAGNOSTICS MARKET FOR PROTEOLYTIC ENZYMES,
BY COUNTRY, 2023–2030 (USD MILLION) 140
TABLE 109 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR PROTEOLYTIC ENZYMES,
BY COUNTRY, 2023–2030 (USD MILLION) 140
TABLE 110 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR PROTEOLYTIC ENZYMES,
BY COUNTRY, 2023–2030 (USD MILLION) 141
TABLE 111 DILUENTS AVAILABLE IN MARKET 141
TABLE 112 TISSUE DIAGNOSTICS MARKET FOR DILUENTS, BY REGION,
2023–2030 (USD MILLION) 142
TABLE 113 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR DILUENTS, BY COUNTRY, 2023–2030 (USD MILLION) 142
TABLE 114 EUROPE: TISSUE DIAGNOSTICS MARKET FOR DILUENTS, BY COUNTRY,
2023–2030 (USD MILLION) 142
TABLE 115 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR DILUENTS, BY COUNTRY,
2023–2030 (USD MILLION) 143
TABLE 116 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR DILUENTS, BY COUNTRY, 2023–2030 (USD MILLION) 143
TABLE 117 OTHER REAGENTS AVAILABLE IN MARKET 144
TABLE 118 TISSUE DIAGNOSTICS MARKET FOR OTHER REAGENTS, BY REGION,
2023–2030 (USD MILLION) 144
TABLE 119 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR OTHER REAGENTS,
BY COUNTRY, 2023–2030 (USD MILLION) 145
TABLE 120 EUROPE: TISSUE DIAGNOSTICS MARKET FOR OTHER REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION) 145
TABLE 121 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR OTHER REAGENTS,
BY COUNTRY, 2023–2030 (USD MILLION) 145
TABLE 122 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR OTHER REAGENTS,
BY COUNTRY, 2023–2030 (USD MILLION) 146
TABLE 123 PROBES AVAILABLE IN MARKET 146
TABLE 124 TISSUE DIAGNOSTICS MARKET FOR PROBES, BY REGION,
2023–2030 (USD MILLION) 147
TABLE 125 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR PROBES, BY COUNTRY, 2023–2030 (USD MILLION) 147
TABLE 126 EUROPE: TISSUE DIAGNOSTICS MARKET FOR PROBES, BY COUNTRY,
2023–2030 (USD MILLION) 147
TABLE 127 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR PROBES, BY COUNTRY,
2023–2030 (USD MILLION) 148
TABLE 128 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR PROBES, BY COUNTRY, 2023–2030 (USD MILLION) 148
TABLE 129 TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE,
2023–2030 (USD MILLION) 149
TABLE 130 TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION,
2023–2030 (USD MILLION) 149
TABLE 131 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS,
BY COUNTRY, 2023–2030 (USD MILLION) 149
TABLE 132 EUROPE: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY,
2023–2030 (USD MILLION) 150
TABLE 133 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION) 150
TABLE 134 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION) 150
TABLE 135 TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE,
2023–2030 (USD MILLION) 151
TABLE 136 TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY REGION,
2023–2030 (USD MILLION) 151
TABLE 137 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION) 152
TABLE 138 EUROPE: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS,
BY COUNTRY, 2023–2030 (USD MILLION) 152
TABLE 139 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS,
BY COUNTRY, 2023–2030 (USD MILLION) 152
TABLE 140 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS,
BY COUNTRY, 2023–2030 (USD MILLION) 153
TABLE 141 H&E STAINERS AVAILABLE IN MARKET 153
TABLE 142 TISSUE DIAGNOSTICS MARKET FOR H&E STAINERS, BY REGION,
2023–2030 (USD MILLION) 154
TABLE 143 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR H&E STAINERS,
BY COUNTRY, 2023–2030 (USD MILLION) 154
TABLE 144 EUROPE: TISSUE DIAGNOSTICS MARKET FOR H&E STAINERS, BY COUNTRY,
2023–2030 (USD MILLION) 154
TABLE 145 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR H&E STAINERS, BY COUNTRY, 2023–2030 (USD MILLION) 155
TABLE 146 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR H&E STAINERS, BY COUNTRY, 2023–2030 (USD MILLION) 155
TABLE 147 SPECIAL STAINERS AVAILABLE IN MARKET 156
TABLE 148 TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINERS, BY REGION,
2023–2030 (USD MILLION) 156
TABLE 149 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINERS,
BY COUNTRY, 2023–2030 (USD MILLION) 156
TABLE 150 EUROPE: TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINERS, BY COUNTRY, 2023–2030 (USD MILLION) 157
TABLE 151 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINERS,
BY COUNTRY, 2023–2030 (USD MILLION) 157
TABLE 152 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINERS,
Y COUNTRY, 2023–2030 (USD MILLION) 157
TABLE 153 IHC STAINERS AVAILABLE IN MARKET 158
TABLE 154 TISSUE DIAGNOSTICS MARKET FOR IHC STAINERS, BY REGION,
2023–2030 (USD MILLION) 159
TABLE 155 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR IHC STAINERS, BY COUNTRY, 2023–2030 (USD MILLION) 159
TABLE 156 EUROPE: TISSUE DIAGNOSTICS MARKET FOR IHC STAINERS, BY COUNTRY,
2023–2030 (USD MILLION) 159
TABLE 157 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR IHC STAINERS, BY COUNTRY, 2023–2030 (USD MILLION) 160
TABLE 158 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR IHC STAINERS, BY COUNTRY, 2023–2030 (USD MILLION) 160
TABLE 159 MICROTOMES AVAILABLE IN MARKET 161
TABLE 160 TISSUE DIAGNOSTICS MARKET FOR MICROTOMES, BY REGION,
2023–2030 (USD MILLION) 161
TABLE 161 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR MICROTOMES, BY COUNTRY, 2023–2030 (USD MILLION) 162
TABLE 162 EUROPE: TISSUE DIAGNOSTICS MARKET FOR MICROTOMES, BY COUNTRY,
2023–2030 (USD MILLION) 162
TABLE 163 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR MICROTOMES, BY COUNTRY, 2023–2030 (USD MILLION) 162
TABLE 164 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR MICROTOMES, BY COUNTRY, 2023–2030 (USD MILLION) 163
TABLE 165 DIGITAL PATHOLOGY SCANNERS AVAILABLE IN MARKET 163
TABLE 166 TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY SCANNERS, BY REGION, 2023–2030 (USD MILLION) 164
TABLE 167 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY SCANNERS, BY COUNTRY, 2023–2030 (USD MILLION) 164
TABLE 168 EUROPE: TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY SCANNERS,
BY COUNTRY, 2023–2030 (USD MILLION) 165
TABLE 169 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY SCANNERS, BY COUNTRY, 2023–2030 (USD MILLION) 165
TABLE 170 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY SCANNERS, BY COUNTRY, 2023–2030 (USD MILLION) 165
TABLE 171 TISSUE PROCESSING SYSTEMS AVAILABLE IN MARKET 166
TABLE 172 TISSUE DIAGNOSTICS MARKET FOR TISSUE PROCESSING SYSTEMS, BY REGION, 2023–2030 (USD MILLION) 167
TABLE 173 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION) 167
TABLE 174 EUROPE: TISSUE DIAGNOSTICS MARKET FOR TISSUE PROCESSING SYSTEMS,
BY COUNTRY, 2023–2030 (USD MILLION) 167
TABLE 175 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION) 168
TABLE 176 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION) 168
TABLE 177 OTHER INSTRUMENTS AVAILABLE IN MARKET 169
TABLE 178 TISSUE DIAGNOSTICS MARKET FOR OTHER INSTRUMENTS, BY REGION,
2023–2030 (USD MILLION) 169
TABLE 179 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR OTHER INSTRUMENTS,
BY COUNTRY, 2023–2030 (USD MILLION) 169
TABLE 180 EUROPE: TISSUE DIAGNOSTICS MARKET FOR OTHER INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION) 170
TABLE 181 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR OTHER INSTRUMENTS,
BY COUNTRY, 2023–2030 (USD MILLION) 170
TABLE 182 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR OTHER INSTRUMENTS,
BY COUNTRY, 2023–2030 (USD MILLION) 170
TABLE 183 TISSUE DIAGNOSTICS MARKET FOR SOFTWARE, BY REGION,
2023–2030 (USD MILLION) 171
TABLE 184 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION) 171
TABLE 185 EUROPE: TISSUE DIAGNOSTICS MARKET FOR SOFTWARE, BY COUNTRY,
2023–2030 (USD MILLION) 172
TABLE 186 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION) 172
TABLE 187 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION) 172
TABLE 188 TISSUE DIAGNOSTICS MARKET FOR SERVICES, BY REGION,
2023–2030 (USD MILLION) 173
TABLE 189 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 173
TABLE 190 EUROPE: TISSUE DIAGNOSTICS MARKET FOR SERVICES, BY COUNTRY,
2023–2030 (USD MILLION) 174
TABLE 191 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR SERVICES, BY COUNTRY,
2023–2030 (USD MILLION) 174
TABLE 192 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 174
TABLE 193 TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 176
TABLE 194 TISSUE DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY REGION, 2023–2030 (USD MILLION) 177
TABLE 195 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2023–2030 (USD MILLION) 178
TABLE 196 EUROPE: TISSUE DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY,
BY COUNTRY, 2023–2030 (USD MILLION) 178
TABLE 197 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY,
BY COUNTRY, 2023–2030 (USD MILLION) 178
TABLE 198 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2023–2030 (USD MILLION) 179
TABLE 199 TISSUE DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION,
2023–2030 (USD MILLION) 180
TABLE 200 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION,
BY COUNTRY, 2023–2030 (USD MILLION) 180
TABLE 201 EUROPE: TISSUE DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION,
BY COUNTRY, 2023–2030 (USD MILLION) 181
TABLE 202 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION,
BY COUNTRY, 2023–2030 (USD MILLION) 181
TABLE 203 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION,
BY COUNTRY, 2023–2030 (USD MILLION) 181
TABLE 204 TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY, BY REGION,
2023–2030 (USD MILLION) 182
TABLE 205 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY,
BY COUNTRY, 2023–2030 (USD MILLION) 183
TABLE 206 EUROPE: TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 183
TABLE 207 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY,
BY COUNTRY, 2023–2030 (USD MILLION) 183
TABLE 208 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY,
BY COUNTRY, 2023–2030 (USD MILLION) 184
TABLE 209 TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINING, BY REGION,
2023–2030 (USD MILLION) 184
TABLE 210 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINING,
BY COUNTRY, 2023–2030 (USD MILLION) 185
TABLE 211 EUROPE: TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINING, BY COUNTRY, 2023–2030 (USD MILLION) 185
TABLE 212 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINING,
BY COUNTRY, 2023–2030 (USD MILLION) 185
TABLE 213 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINING,
BY COUNTRY, 2023–2030 (USD MILLION) 186
TABLE 214 GLOBAL CANCER INCIDENCE, 2020 VS. 2040 188
TABLE 215 TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023–2030 (USD MILLION) 189
TABLE 216 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040 190
TABLE 217 TISSUE DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION,
2023–2030 (USD MILLION) 190
TABLE 218 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR BREAST CANCER,
BY COUNTRY, 2023–2030 (USD MILLION) 190
TABLE 219 EUROPE: TISSUE DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 191
TABLE 220 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 191
TABLE 221 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR BREAST CANCER,
BY COUNTRY, 2023–2030 (USD MILLION) 191
TABLE 222 COLON CANCER INCIDENCE, BY REGION, 2020 VS. 2040 192
TABLE 223 TISSUE DIAGNOSTICS MARKET FOR GASTRIC CANCER, BY REGION,
2023–2030 (USD MILLION) 193
TABLE 224 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR GASTRIC CANCER,
BY COUNTRY, 2023–2030 (USD MILLION) 193
TABLE 225 EUROPE: TISSUE DIAGNOSTICS MARKET FOR GASTRIC CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 193
TABLE 226 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR GASTRIC CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 194
TABLE 227 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR GASTRIC CANCER,
BY COUNTRY, 2023–2030 (USD MILLION) 194
TABLE 228 HODGKIN LYMPHOMA INCIDENCE, BY REGION, 2020 VS. 2040 195
TABLE 229 NON-HODGKIN LYMPHOMA INCIDENCE, BY REGION, 2020 VS. 2040 195
TABLE 230 TISSUE DIAGNOSTICS MARKET FOR LYMPHOMA, BY REGION,
2023–2030 (USD MILLION) 195
TABLE 231 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR LYMPHOMA, BY COUNTRY, 2023–2030 (USD MILLION) 196
TABLE 232 EUROPE: TISSUE DIAGNOSTICS MARKET FOR LYMPHOMA, BY COUNTRY,
2023–2030 (USD MILLION) 196
TABLE 233 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR LYMPHOMA, BY COUNTRY, 2023–2030 (USD MILLION) 196
TABLE 234 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR LYMPHOMA, BY COUNTRY, 2023–2030 (USD MILLION) 197
TABLE 235 PROSTATE CANCER INCIDENCE, BY REGION, 2020 VS. 2040 197
TABLE 236 TISSUE DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY REGION,
2023–2030 (USD MILLION) 198
TABLE 237 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR PROSTATE CANCER,
BY COUNTRY, 2023–2030 (USD MILLION) 198
TABLE 238 EUROPE: TISSUE DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 198
TABLE 239 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR PROSTATE CANCER,
BY COUNTRY, 2023–2030 (USD MILLION) 199
TABLE 240 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR PROSTATE CANCER,
BY COUNTRY, 2023–2030 (USD MILLION) 199
TABLE 241 TISSUE DIAGNOSTICS MARKET FOR NON-SMALL CELL LUNG CANCER, BY REGION, 2023–2030 (USD MILLION) 200
TABLE 242 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 200
TABLE 243 EUROPE: TISSUE DIAGNOSTICS MARKET FOR NON-SMALL CELL LUNG CANCER,
BY COUNTRY, 2023–2030 (USD MILLION) 201
TABLE 244 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 201
TABLE 245 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 201
TABLE 246 TISSUE DIAGNOSTICS MARKET FOR OTHER DISEASES, BY REGION,
2023–2030 (USD MILLION) 202
TABLE 247 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR OTHER DISEASES,
BY COUNTRY, 2023–2030 (USD MILLION) 203
TABLE 248 EUROPE: TISSUE DIAGNOSTICS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 203
TABLE 249 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 203
TABLE 250 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR OTHER DISEASES,
BY COUNTRY, 2023–2030 (USD MILLION) 204
TABLE 251 US: NUMBER OF TISSUE DIAGNOSTICS TESTS, BY SAMPLE TYPE,
2023–2030 (NO. OF TESTS) 205
TABLE 252 TISSUE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 207
TABLE 253 TISSUE DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION,
2023–2030 (USD MILLION) 208
TABLE 254 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 208
TABLE 255 EUROPE: TISSUE DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY,
2023–2030 (USD MILLION) 209
TABLE 256 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 209
TABLE 257 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 209
TABLE 258 TISSUE DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, BY REGION, 2023–2030 (USD MILLION) 210
TABLE 259 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 210
TABLE 260 EUROPE: TISSUE DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES,
BY COUNTRY, 2023–2030 (USD MILLION) 211
TABLE 261 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES,
BY COUNTRY, 2023–2030 (USD MILLION) 211
TABLE 262 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 211
TABLE 263 TISSUE DIAGNOSTICS MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD MILLION) 212
TABLE 264 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 212
TABLE 265 EUROPE: TISSUE DIAGNOSTICS MARKET FOR PHARMACEUTICAL COMPANIES,
BY COUNTRY, 2023–2030 (USD MILLION) 213
TABLE 266 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 213
TABLE 267 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 213
TABLE 268 CONTRACT RESEARCH ORGANIZATIONS FOR ONCOLOGY DIAGNOSTICS 214
TABLE 269 TISSUE DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS,
BY REGION, 2023–2030 (USD MILLION) 214
TABLE 270 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 215
TABLE 271 EUROPE: TISSUE DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 215
TABLE 272 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 215
TABLE 273 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 216
TABLE 274 TISSUE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION,
2023–2030 (USD MILLION) 217
TABLE 275 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR OTHER END USERS,
BY COUNTRY, 2023–2030 (USD MILLION) 217
TABLE 276 EUROPE: TISSUE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 217
TABLE 277 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR OTHER END USERS,
BY COUNTRY, 2023–2030 (USD MILLION) 218
TABLE 278 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR OTHER END USERS,
BY COUNTRY, 2023–2030 (USD MILLION) 218
TABLE 279 TISSUE DIAGNOSTICS MARKET, BY REGION, 2023–2030 (USD MILLION) 220
TABLE 280 NORTH AMERICA: MACROECONOMIC INDICATORS 221
TABLE 281 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 222
TABLE 282 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 223
TABLE 283 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION) 223
TABLE 284 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023–2030 (USD MILLION) 223
TABLE 285 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE,
2023–2030 (USD MILLION) 224
TABLE 286 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE,
2023–2030 (USD MILLION) 224
TABLE 287 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION) 225
TABLE 288 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 225
TABLE 289 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 225
TABLE 290 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY DISEASE,
2023–2030 (USD MILLION) 226
TABLE 291 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 226
TABLE 292 US CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 227
TABLE 293 US: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 228
TABLE 294 US: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE,
2023–2030 (USD MILLION) 228
TABLE 295 US: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE,
2023–2030 (USD MILLION) 228
TABLE 296 US: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE,
2023–2030 (USD MILLION) 229
TABLE 297 US: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE,
2023–2030 (USD MILLION) 229
TABLE 298 US: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE,
2023–2030 (USD MILLION) 230
TABLE 299 US: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 230
TABLE 300 US: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 230
TABLE 301 US: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023–2030 (USD MILLION) 231
TABLE 302 US: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 231
TABLE 303 CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 232
TABLE 304 CANADA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 232
TABLE 305 CANADA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE,
2023–2030 (USD MILLION) 233
TABLE 306 CANADA: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE,
2023–2030 (USD MILLION) 233
TABLE 307 CANADA: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE,
2023–2030 (USD MILLION) 233
TABLE 308 CANADA: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE,
2023–2030 (USD MILLION) 234
TABLE 309 CANADA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE,
2023–2030 (USD MILLION) 234
TABLE 310 CANADA: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 235
TABLE 311 CANADA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 235
TABLE 312 CANADA: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023–2030 (USD MILLION) 235
TABLE 313 CANADA: TISSUE DIAGNOSTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 236
TABLE 314 EUROPE: KEY MACROECONOMIC INDICATORS 237
TABLE 315 EUROPE: TISSUE DIAGNOSTICS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 238
TABLE 316 EUROPE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 238
TABLE 317 EUROPE: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE,
2023–2030 (USD MILLION) 238
TABLE 318 EUROPE: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE,
2023–2030 (USD MILLION) 239
TABLE 319 EUROPE: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE,
2023–2030 (USD MILLION) 239
TABLE 320 EUROPE: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE,
2023–2030 (USD MILLION) 239
TABLE 321 EUROPE: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE,
2023–2030 (USD MILLION) 240
TABLE 322 EUROPE: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 240
TABLE 323 EUROPE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 240
TABLE 324 EUROPE: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023–2030 (USD MILLION) 241
TABLE 325 EUROPE: TISSUE DIAGNOSTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 241
TABLE 326 GERMANY: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 242
TABLE 327 GERMANY: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 243
TABLE 328 GERMANY: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE,
2023–2030 (USD MILLION) 243
TABLE 329 GERMANY: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE,
2023–2030 (USD MILLION) 243
TABLE 330 GERMANY: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE,
2023–2030 (USD MILLION) 244
TABLE 331 GERMANY: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE,
2023–2030 (USD MILLION) 244
TABLE 332 GERMANY: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE,
2023–2030 (USD MILLION) 245
TABLE 333 GERMANY: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS,
BY TYPE, 2023–2030 (USD MILLION) 245
TABLE 334 GERMANY: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 245
TABLE 335 GERMANY: TISSUE DIAGNOSTICS MARKET, BY DISEASE,
2023–2030 (USD MILLION) 246
TABLE 336 GERMANY: TISSUE DIAGNOSTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 246
TABLE 337 FRANCE: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 247
TABLE 338 FRANCE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 248
TABLE 339 FRANCE: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE,
2023–2030 (USD MILLION) 248
TABLE 340 FRANCE: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE,
2023–2030 (USD MILLION) 248
TABLE 341 FRANCE: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE,
2023–2030 (USD MILLION) 249
TABLE 342 FRANCE: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE,
2023–2030 (USD MILLION) 249
TABLE 343 FRANCE: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE,
2023–2030 (USD MILLION) 250
TABLE 344 FRANCE: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 250
TABLE 345 FRANCE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 250
TABLE 346 FRANCE: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023–2030 (USD MILLION) 251
TABLE 347 FRANCE: TISSUE DIAGNOSTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 251
TABLE 348 UK: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 252
TABLE 349 UK: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE,
2023–2030 (USD MILLION) 252
TABLE 350 UK: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE,
2023–2030 (USD MILLION) 253
TABLE 351 UK: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE,
2023–2030 (USD MILLION) 253
TABLE 352 UK: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE,
2023–2030 (USD MILLION) 253
TABLE 353 UK: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE,
2023–2030 (USD MILLION) 254
TABLE 354 UK: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 254
TABLE 355 UK: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 254
TABLE 356 UK: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023–2030 (USD MILLION) 255
TABLE 357 UK: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 255
TABLE 358 ITALY: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 256
TABLE 359 ITALY: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 257
TABLE 360 ITALY: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE,
2023–2030 (USD MILLION) 257
TABLE 361 ITALY: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE,
2023–2030 (USD MILLION) 257
TABLE 362 ITALY: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE,
2023–2030 (USD MILLION) 258
TABLE 363 ITALY: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE,
2023–2030 (USD MILLION) 258
TABLE 364 ITALY: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE,
2023–2030 (USD MILLION) 259
TABLE 365 ITALY: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 259
TABLE 366 ITALY: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 259
TABLE 367 ITALY: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023–2030 (USD MILLION) 260
TABLE 368 ITALY: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 260
TABLE 369 SPAIN: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 261
TABLE 370 SPAIN: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE,
2023–2030 (USD MILLION) 261
TABLE 371 SPAIN: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE,
2023–2030 (USD MILLION) 262
TABLE 372 SPAIN: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE,
2023–2030 (USD MILLION) 262
TABLE 373 SPAIN: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE,
2023–2030 (USD MILLION) 262
TABLE 374 SPAIN: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE,
2023–2030 (USD MILLION) 263
TABLE 375 SPAIN: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 263
TABLE 376 SPAIN: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 263
TABLE 377 SPAIN: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023–2030 (USD MILLION) 264
TABLE 378 SPAIN: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 264
TABLE 379 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 265
TABLE 380 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION) 265
TABLE 381 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023–2030 (USD MILLION) 266
TABLE 382 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE,
2023–2030 (USD MILLION) 266
TABLE 383 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 266
TABLE 384 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION) 267
TABLE 385 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 267
TABLE 386 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 267
TABLE 387 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET, BY DISEASE,
2023–2030 (USD MILLION) 268
TABLE 388 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 268
TABLE 389 ASIA PACIFIC: KEY MACROECONOMIC INDICATORS 269
TABLE 390 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 270
TABLE 391 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 271
TABLE 392 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION) 271
TABLE 393 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE,
2023–2030 (USD MILLION) 271
TABLE 394 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE,
2023–2030 (USD MILLION) 272
TABLE 395 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE,
2023–2030 (USD MILLION) 272
TABLE 396 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE,
2023–2030 (USD MILLION) 273
TABLE 397 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS,
BY TYPE, 2023–2030 (USD MILLION) 273
TABLE 398 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 273
TABLE 399 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY DISEASE,
2023–2030 (USD MILLION) 274
TABLE 400 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 274
TABLE 401 CHINA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 275
TABLE 402 CHINA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE,
2023–2030 (USD MILLION) 275
TABLE 403 CHINA: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE,
2023–2030 (USD MILLION) 276
TABLE 404 CHINA: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE,
2023–2030 (USD MILLION) 276
TABLE 405 CHINA: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE,
2023–2030 (USD MILLION) 276
TABLE 406 CHINA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE,
2023–2030 (USD MILLION) 277
TABLE 407 CHINA: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 277
TABLE 408 CHINA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 277
TABLE 409 CHINA: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023–2030 (USD MILLION) 278
TABLE 410 CHINA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 278
TABLE 411 CANCER INCIDENCE, BY CANCER TYPE (JAPAN), 2020 VS. 2040 279
TABLE 412 JAPAN: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 280
TABLE 413 JAPAN: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE,
2023–2030 (USD MILLION) 280
TABLE 414 JAPAN: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE,
2023–2030 (USD MILLION) 280
TABLE 415 JAPAN: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE,
2023–2030 (USD MILLION) 281
TABLE 416 JAPAN: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE,
2023–2030 (USD MILLION) 281
TABLE 417 JAPAN: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE,
2023–2030 (USD MILLION) 282
TABLE 418 JAPAN: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 282
TABLE 419 JAPAN: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 282
TABLE 420 JAPAN: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023–2030 (USD MILLION) 283
TABLE 421 JAPAN: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 283
TABLE 422 INDIA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 284
TABLE 423 INDIA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE,
2023–2030 (USD MILLION) 285
TABLE 424 INDIA: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE,
2023–2030 (USD MILLION) 285
TABLE 425 INDIA: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE,
2023–2030 (USD MILLION) 285
TABLE 426 INDIA: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE,
2023–2030 (USD MILLION) 286
TABLE 427 INDIA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE,
2023–2030 (USD MILLION) 286
TABLE 428 INDIA: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 287
TABLE 429 INDIA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 287
TABLE 430 INDIA: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023–2030 (USD MILLION) 287
TABLE 431 INDIA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 288
TABLE 432 REST OF ASIA PACIFIC: CANCER INCIDENCE, 2020 VS. 2040 288
TABLE 433 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 289
TABLE 434 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES,
BY TYPE, 2023–2030 (USD MILLION) 289
TABLE 435 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE, 2023–2030 (USD MILLION) 289
TABLE 436 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE,
2023–2030 (USD MILLION) 290
TABLE 437 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 290
TABLE 438 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS,
BY TYPE, 2023–2030 (USD MILLION) 291
TABLE 439 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 291
TABLE 440 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 291
TABLE 441 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY DISEASE,
2023–2030 (USD MILLION) 292
TABLE 442 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 292
TABLE 443 LATIN AMERICA: KEY MACROECONOMIC INDICATORS 293
TABLE 444 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 293
TABLE 445 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 294
TABLE 446 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION) 294
TABLE 447 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE,
2023–2030 (USD MILLION) 294
TABLE 448 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE,
2023–2030 (USD MILLION) 295
TABLE 449 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE,
2023–2030 (USD MILLION) 295
TABLE 450 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION) 296
TABLE 451 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS,
BY TYPE, 2023–2030 (USD MILLION) 296
TABLE 452 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 296
TABLE 453 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY DISEASE,
2023–2030 (USD MILLION) 297
TABLE 454 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 297
TABLE 455 BRAZIL: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 298
TABLE 456 BRAZIL: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE,
2023–2030 (USD MILLION) 298
TABLE 457 BRAZIL: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE,
2023–2030 (USD MILLION) 299
TABLE 458 BRAZIL: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE,
2023–2030 (USD MILLION) 299
TABLE 459 BRAZIL: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE,
2023–2030 (USD MILLION) 299
TABLE 460 BRAZIL: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE,
2023–2030 (USD MILLION) 300
TABLE 461 BRAZIL: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 300
TABLE 462 BRAZIL: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 300
TABLE 463 BRAZIL: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023–2030 (USD MILLION) 301
TABLE 464 BRAZIL: TISSUE DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 301
TABLE 465 MEXICO: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 302
TABLE 466 MEXICO: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE,
2023–2030 (USD MILLION) 302
TABLE 467 MEXICO: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY TYPE,
2023–2030 (USD MILLION) 303
TABLE 468 MEXICO: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE,
2023–2030 (USD MILLION) 303
TABLE 469 MEXICO: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE,
2023–2030 (USD MILLION) 303
TABLE 470 MEXICO: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE,
2023–2030 (USD MILLION) 304
TABLE 471 MEXICO: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 304
TABLE 472 MEXICO: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 304
TABLE 473 MEXICO: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2023–2030 (USD MILLION) 305
TABLE 474 MEXICO: TISSUE DIAGNOSTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 305
TABLE 475 REST OF LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 306
TABLE 476 REST OF LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES,
BY TYPE, 2023–2030 (USD MILLION) 306
TABLE 477 REST OF LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES,
BY TYPE, 2023–2030 (USD MILLION) 306
TABLE 478 REST OF LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE, 2023–2030 (USD MILLION) 307
TABLE 479 REST OF LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 307
TABLE 480 REST OF LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS,
BY TYPE, 2023–2030 (USD MILLION) 308
TABLE 481 REST OF LATIN AMERICA: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 308
TABLE 482 REST OF LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 308
TABLE 483 REST OF LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY DISEASE,
2023–2030 (USD MILLION) 309
TABLE 484 REST OF LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 309
TABLE 485 MIDDLE EAST & AFRICA: KEY MACROECONOMIC INDICATORS 310
TABLE 486 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 310
TABLE 487 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES,
BY TYPE, 2023–2030 (USD MILLION) 311
TABLE 488 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES,
BY TYPE, 2023–2030 (USD MILLION) 311
TABLE 489 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET FOR KITS, BY TYPE,
2023–2030 (USD MILLION) 311
TABLE 490 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 312
TABLE 491 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS,
BY TYPE, 2023–2030 (USD MILLION) 312
TABLE 492 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 313
TABLE 493 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 313
TABLE 494 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY DISEASE,
2023–2030 (USD MILLION) 313
TABLE 495 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY END USER,
2023–2030 (USD MILLION) 314
TABLE 496 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022–2025 315
TABLE 497 TISSUE DIAGNOSTICS MARKET: DEGREE OF COMPETITION 318
TABLE 498 REGION FOOTPRINT 323
TABLE 499 PRODUCT & SERVICE FOOTPRINT 324
TABLE 500 APPLICATION FOOTPRINT 325
TABLE 501 END USER FOOTPRINT 325
TABLE 502 DETAILED LIST OF KEY STARTUPS/SMES 328
TABLE 503 COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 329
TABLE 504 TISSUE DIAGNOSTICS MARKET: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–DECEMBER 2025 330
TABLE 505 TISSUE DIAGNOSTICS MARKET: DEALS, JANUARY 2022–DECEMBER 2025 331
TABLE 506 TISSUE DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2022–DECEMBER 2025 332
TABLE 507 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 334
TABLE 508 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 335
TABLE 509 F. HOFFMAN-LA ROCHE LTD.: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–OCTOBER 2025 337
TABLE 510 DANAHER CORPORATION: COMPANY OVERVIEW 340
TABLE 511 DANAHER CORPORATION: PRODUCTS OFFERED 341
TABLE 512 DANAHER CORPORATION: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–OCTOBER 2025 343
TABLE 513 DANAHER CORPORATION: DEALS, JANUARY 2022–OCTOBER 2025 343
TABLE 514 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 346
TABLE 515 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED 347
TABLE 516 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2022–OCTOBER 2025 348
TABLE 517 PHC HOLDINGS CORPORATION: COMPANY OVERVIEW 350
TABLE 518 PHC HOLDINGS CORPORATION: PRODUCTS OFFERED 351
TABLE 519 PHC HOLDINGS CORPORATION: PRODUCT APPROVALS,
JANUARY 2022–OCTOBER 2025 352
TABLE 520 PHC HOLDINGS CORPORATION: DEALS, JANUARY 2022–OCTOBER 2025 352
TABLE 521 MERCK KGAA: COMPANY OVERVIEW 354
TABLE 522 MERCK KGAA: PRODUCTS OFFERED 355
TABLE 523 MERCK KGAA: EXPANSIONS, JANUARY 2022–OCTOBER 2025 356
TABLE 524 ABBOTT: COMPANY OVERVIEW 358
TABLE 525 ABBOTT: PRODUCTS OFFERED 360
TABLE 526 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 361
TABLE 527 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED 362
TABLE 528 BECTON, DICKINSON AND COMPANY: EXPANSIONS,
JANUARY 2022–OCTOBER 2025 363
TABLE 529 SYSMEX CORPORATION: COMPANY OVERVIEW 364
TABLE 530 SYSMEX CORPORATION: PRODUCTS OFFERED 365
TABLE 531 SYSMEX CORPORATION: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–OCTOBER 2025 366
TABLE 532 SYSMEX CORPORATION: DEALS, JANUARY 2022–OCTOBER 2025 366
TABLE 533 SAKURA FINETEK JAPAN CO., LTD.: COMPANY OVERVIEW 367
TABLE 534 SAKURA FINETEK JAPAN CO., LTD.: PRODUCTS OFFERED 367
TABLE 535 SAKURA FINETEK JAPAN CO., LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–OCTOBER 2025 368
TABLE 536 SAKURA FINETEK JAPAN CO., LTD.: DEALS, JANUARY 2022–OCTOBER 2025 370
TABLE 537 SAKURA FINETEK JAPAN CO., LTD.: EXPANSIONS, JANUARY 2022–OCTOBER 2025 370
TABLE 538 BIOGENEX: COMPANY OVERVIEW 371
TABLE 539 BIOGENEX: PRODUCTS OFFERED 371
TABLE 540 BIOGENEX: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–OCTOBER 2025 372
TABLE 541 BIO SB: COMPANY OVERVIEW 373
TABLE 542 BIO SB: PRODUCTS OFFERED 374
TABLE 543 CELL SIGNALING TECHNOLOGY, INC.: COMPANY OVERVIEW 375
TABLE 544 CELL SIGNALING TECHNOLOGY, INC.: PRODUCTS OFFERED 375
TABLE 545 CELL SIGNALING TECHNOLOGY, INC.: DEALS, JANUARY 2022–OCTOBER 2025 375
TABLE 546 HISTO-LINE LABORATORIES: COMPANY OVERVIEW 377
TABLE 547 HISTO-LINE LABORATORIES: PRODUCTS OFFERED 377
TABLE 548 SLEE MEDICAL GMBH: COMPANY OVERVIEW 379
TABLE 549 SLEE MEDICAL GMBH: PRODUCTS OFFERED 379
TABLE 550 AMOS SCIENTIFIC PTY LTD.: COMPANY OVERVIEW 381
TABLE 551 JINHUA YIDI MEDICAL APPLIANCE CO., LTD.: COMPANY OVERVIEW 382
TABLE 552 MEDITE MEDICAL GMBH: COMPANY OVERVIEW 383
TABLE 553 SLMP, LLC.: COMPANY OVERVIEW 384
TABLE 554 KONFOONG BIOINFORMATION TECH CO., LTD (KFBIO): COMPANY OVERVIEW 385
TABLE 555 DIAGNOSTIC BIOSYSTEMS INC.: COMPANY OVERVIEW 386
TABLE 556 3DHISTECH LTD.: COMPANY OVERVIEW 387
TABLE 557 RWD LIFE SCIENCE CO., LTD.: COMPANY OVERVIEW 388
TABLE 558 DAKEWE: COMPANY OVERVIEW 389
TABLE 559 BATTERY VENTURES (ENZO BIOCHEM INC.): COMPANY OVERVIEW 390
TABLE 560 BIOCARE MEDICAL, LLC.: COMPANY OVERVIEW 391
TABLE 561 MILESTONE SRL: COMPANY OVERVIEW 392
TABLE 562 BIO-OPTICA MILANO SPA: COMPANY OVERVIEW 393
TABLE 563 BIOGNOST D.O.O.: COMPANY OVERVIEW 394
TABLE 564 OPTRASCAN: COMPANY OVERVIEW 395
TABLE 565 CLARAPATH: COMPANY OVERVIEW 396
TABLE 566 IMPACT ANALYSIS OF SUPPLY AND DEMAND-SIDE FACTORS 408
TABLE 567 RESAERCH ASSUMPTIONS 410
TABLE 568 RISK ASSESSMENT 411

LIST OF FIGURES

FIGURE 1 TISSUE DIAGNOSTICS MARKET SEGMENTATION AND REGIONAL SCOPE 40
FIGURE 2 MARKET SCENARIO 44
FIGURE 3 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN TISSUE DIAGNOSTICS MARKET, 2022–2025 45
FIGURE 4 DISRUPTIVE TRENDS IMPACTING GROWTH OF TISSUE DIAGNOSTICS MARKET 46
FIGURE 5 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS IN TISSUE DIAGNOSTICS MARKET, 2024 47
FIGURE 6 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 48
FIGURE 7 GROWING PREVALENCE OF CANCER CASES TO DRIVE MARKET 49
FIGURE 8 CONSUMABLES SEGMENT TO HAVE LARGEST MARKET DURING FORECAST PERIOD 50
FIGURE 9 IMMUNOHISTOCHEMISTRY SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 50
FIGURE 10 BREAST CANCER SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 51
FIGURE 11 HOSPITALS SEGMENT TO HAVE LARGEST SHARE DURING FORECAST PERIOD 51
FIGURE 12 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 52
FIGURE 13 TISSUE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 53
FIGURE 14 NEWLY APPROVED PERSONALIZED MEDICINES (% OF ALL NEWLY APPROVED DRUGS), 2015–2024 61
FIGURE 15 TISSUE DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 66
FIGURE 16 TISSUE DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS 72
FIGURE 17 TISSUE DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS 73
FIGURE 18 TISSUE DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS 74
FIGURE 19 TISSUE DIAGNOSTICS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 80
FIGURE 20 TISSUE DIAGNOSTICS MARKET: INVESTMENT AND FUNDING SCENARIO 81
FIGURE 21 PATENT ANALYSIS FOR TISSUE PROCESSING SYSTEMS,
JANUARY 2015–DECEMBER 2024 90
FIGURE 22 MARKET POTENTIAL OF AI IN TISSUE DIAGNOSTICS MARKET 93
FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER 103
FIGURE 24 KEY BUYING CRITERIA, BY END USER 104
FIGURE 25 NORTH AMERICA TISSUE DIAGNOSTICS MARKET SNAPSHOT 222
FIGURE 26 ASIA PACIFIC TISSUE DIAGNOSTICS MARKET SNAPSHOT 270
FIGURE 27 REVENUE ANALYSIS OF KEY PLAYERS, 2022–2024 (USD MILLION) 317
FIGURE 28 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024 318
FIGURE 29 US MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024 319
FIGURE 30 BRAND COMPARISON 320
FIGURE 31 TISSUE DIAGNOSTICS MARKET: COMPANY EVALUATION
MATRIX (KEY PLAYERS), 2024 322
FIGURE 32 COMPANY FOOTPRINT 323
FIGURE 33 TISSUE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 327
FIGURE 34 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND FIVE-YEAR STOCK
BETA OF KEY VENDORS 329
FIGURE 35 EV/EBITDA OF KEY VENDORS 330
FIGURE 36 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT 335
FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT 341
FIGURE 38 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT 347
FIGURE 39 PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT 351
FIGURE 40 MERCK KGAA: COMPANY SNAPSHOT 355
FIGURE 41 ABBOTT: COMPANY SNAPSHOT 359
FIGURE 42 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT 362
FIGURE 43 SYSMEX CORPORATION: COMPANY SNAPSHOT 365
FIGURE 44 TISSUE DIAGNOSTICS MARKET: RESEARCH DESIGN 397
FIGURE 45 TISSUE DIAGNOTICS MARKET: KEY DATA FROM SECONDARY SOURCES 398
FIGURE 46 LIST OF PRIMARY SOURCES IN TISSUE DIAGNOSTICS MARKET 400
FIGURE 47 TISSUE DIAGNOSTICS MARKET: BREAKDOWN OF PRIMARY INTERVIEWS, BY COMPANY TYPE, DESIGNATION, AND REGION 401
FIGURE 48 TISSUE DIAGNOSTICS MARKET: KEY INSIGHTS FROM PRIMARY EXPERTS 402
FIGURE 49 REVENUE ESTIMATION OF KEY PLAYERS IN TISSUE DIAGNOSTICS MARKET 403
FIGURE 50 TISSUE DIAGNOSTICS MARKET: TOP-DOWN APPROACH 404
FIGURE 51 TISSUE DIAGNOSTICS BASE NUMBER CALCULATION
(SUPPLY-SIDE ANALYSIS), 2024 405
FIGURE 52 TISSUE DIAGNOSTICSMARKET MARKET: CAGR PROJECTIONS 406
FIGURE 53 TISSUE DIAGNOSTICS MARKET: DATA TRIANGULATION 407
FIGURE 54 PARAMETRIC ASSUMPTIONS IN TISSUE DIAGNOSTICS MARKET 409

---

---